98%
921
2 minutes
20
The last 2 decades have witnessed increased research on the role of life events in personality trait development, but few findings appear to be robust. We propose that a key to resolving this issue is incorporating individuals' subjective experiences into the study of event-related development. To test this, we developed and administered a survey about event-related personality change to a representative Dutch sample (N = 5,513, Ages 16-95) and linked their responses to 12-year trajectories of measured Big Five development. Most participants (63%) believed that a life event impacted their personality in the past 10 years, on average 5 years presurvey. These participants, even those who experienced the same event, had markedly heterogenous perceptions of how their traits changed and why each event affected their personality. In preregistered analyses, we examined participants' individual personality trajectories before and after the event that they identified as most impactful. Across events, retrospective perceptions of event-related personality change were significantly correlated with short-term and long-term postevent personality trajectories across Big Five traits (mean rs = .22, .28) and preevent trajectories in all traits except agreeableness (mean r = .16). We also found correspondence between perceived and measured development in analyses of the two most commonly reported personality-changing events: health problems and death of a loved one/family member. Finally, we explored associations between personality development and perceived change-inducing event characteristics. Using these findings, we argue that future research into event-related personality development should de-emphasize mean-level change to focus on individuals' varied experiences of whether, when, how, and why life events have affected their personality. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/pspp0000483 | DOI Listing |
Circ Genom Precis Med
September 2025
Feinberg School of Medicine, Northwestern University, Chicago, IL (Z.C., P.G., A.G., G.W.).
Background: Genetic variation contributes to atrial fibrillation (AF), but its impact may vary with age. The Research Program contains whole-genome sequencing of data from 100 574 adult participants with linked electronic health records.
Methods: We assessed clinical, monogenic, and polygenic associations with AF in a cross-sectional analysis, stratified by age: <45 years (n=22 290), 45 to 60 years (n=26 805), and >60 years (n=51 659).
Immunotherapy
September 2025
aGuangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
JDR Clin Trans Res
September 2025
School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.
Objectives: Socioeconomic status (SES) has a significant effect on the burden of early childhood caries (ECC), yet addressing SES disparities remains challenging. This study aimed to identify and quantify the most impactful mediator linking SES effect to the occurrence of ECC using advanced causal mediation analysis, to inform targeted interventions that reduce SES-related disparities in ECC.
Methods: Data were drawn from the Study of Mothers' and Infants' Life Events, a cohort of 2,182 mother-child dyads recruited from Adelaide's 3 largest public hospitals (2013-2014).
Int J Dermatol
September 2025
Servicio de Dermatología, Hospital Infanta Leonor, Madrid, Spain.
Background: Tildrakizumab has demonstrated high efficacy and a good long-term safety profile, including low malignancy rates, in Phase III trials with 5-year extension. Despite these data, the real-world evidence on patients with psoriasis and a history of cancer is limited.
Objectives: To assess the efficacy and safety of tildrakizumab in a cohort of patients with moderate-to-severe psoriasis and a previous or current history of neoplasia.
Eur J Neurol
September 2025
Pain Treatment and Evaluation Center, CHU Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.
Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.